University of North Carolina at Chapel Hill, Chapel Hill, NC. RATIONALE: In a phase 3 study of the experimental treatment AR101 for peanut allergy, 67.2% of AR101-treated subjects vs 4% of placebo tolerated > _600 mg of peanut protein at exit double-blind, placebocontrolled food challenge (DBPCFC). We determined the single highest tolerated dose (SHTD) at exit and estimated the probability of tolerating each challenge dose < _1000mg for the AR101-and placebo-treated groups. METHODS: SHTDs (mild/no allergy symptoms) at screening and exit DBPCFC were recorded for intention-to-treat (ITT; n5372 AR101; n5124 placebo) and for subjects who completed the study (completer, n5296 AR101; n5116 placebo) (4-17-years-old). Subjects without an exit DBPCFC were assigned the screening SHTD. A discrete hazards model (treatment-group effect; region; screening SHTD) estimated probability of tolerating each exit dose; hazard ratio was determined (Wald statistic). RESULTS: The greatest SHTD at screening was 30mg in both groups (37.6% AR101; 42.7% placebo). At exit DBPCFC, SHTDs for AR101 and placebo ITT, respectively, were 50.3% and 2.4% at 1000mg; 16.9% and 1.6% at 600mg; 9.4% and 4.0% at 300mg; 92% of subjects receiving placebo had SHTD of 1-100mg. The adjusted hazard ratio (AR101:placebo) for the probability of tolerating each challenge dose at the exit DBPCFC was 0.15 (95% CI: 0.11-0.19) for the ITT group and 0.05 (95% CI: 0.03-0.06) for those who completed the study. CONCLUSIONS: AR101 treatment showed a statistically significant treatment effect, consistent with meaningful clinical benefit over placebo. AR101-treated subjects had an 85% increased probability versus placebo to tolerate any dose in the exit challenge < _1000 mg (ITT), increasing to 95% if subjects completed the study.
Risk Factors Associated With Positive Outcomes Of Oral Food Challenges To Peanut In At-Risk Infants
Sharon L. Hwang, MD, and Trong V. Le, MD; Sidney Kimmel Medical College at Thomas Jefferson University/Nemours Alfred I. duPont Hospital for Children, Wilmington, DE. RATIONALE: Food allergy guidelines now recommend early introduction of peanut to at-risk infants as a strategy for prevention of peanut allergy. We aim to identify predictors of peanut oral food challenge (OFC) outcomes. METHODS: A retrospective chart review of infants < _12 months old undergoing peanut OFC from 2016-2018 was conducted. Baseline characteristics, peanut skin prick test (SPT) wheal size, peanut-specific IgE, and Ara h2-specific IgE, if available, were analyzed as predictors of OFC outcomes. Study was IRB approved. RESULTS: Fifty-five peanut OFCs were performed. Fourteen challenges (25%) failed; 7 patients required epinephrine. All patients had skin prick testing performed while 46 patients had peanut sIgE and 28 patients had reflex component testing performed. The median values of Ara h2 sIgE for passed and failed challenges were 0.09 kU/L (range 0.09-0.83 kU/L) and 0.37 kU/L (range 0.09-1.49 kU/L), respectively, which was a statistically significant difference (p50.002). Median values of peanut sIgE between the groups were 0.41 kU/L (range 0.09-7.24) and 1.22kU/L (range 0.22-18.7) (p5 0.034). Median SPT wheal sizes were 3mm (range 0-7mm) and 5mm (range 0-7mm) (p50.014). Failure rates based on age groups of 4-6 months (n515), 7-8 months (n516), and 9-12 months (n524) were 0%, 25%, and 41.7%, respectively. Chi-square test for the trend in proportions demonstrated a significant difference, p5 0.004. CONCLUSIONS: In addition to higher peanut SPT wheal size, peanutspecific IgE, and Ara h2-specific IgE, we identified older age as a key risk factor associated with positive oral food challenges to peanut in at-risk infants. These factors may be used to predict outcomes.
